PD-L1 inhibitors such as Atezolizumab, Durvalumab, and Avelumab further promote the killing ... model of glioblastoma organoids that summarizes the cellular heterogeneity, structure, and function of ...

Capital structure describes the mix of a firm's long-term capital—a mix of debt and equity—that it uses to fund its ongoing operations and future growth. A company's capital structure is ...

Previous trials of neoadjuvant and adjuvant immunotherapy showed clinical benefit in this setting, and perioperative durvalumab combined with neoadjuvant gemcitabine–cisplatin (followed by ...

This trial is designed to compare the ivonescimab combined regimen, a PD-1/VEGF bispecific antibody internally developed by Akeso, with the durvalumab (PD-L1) combined regimen for the first-line ...

Durvalumab, a monoclonal antibody used in combination with chemotherapy, has shown promising results in the NIAGARA trial. This treatment has led to a significant reduction in recurrences and ...

The U.S. Food and Drug Administration has approved Itovebi (inavolisib), in combination with palbociclib (Ibrance) and fulvestrant, for the treatment of adults with endocrine-resistant, PIK3CA ...

Bladder cancers comprise heterogeneous cell populations, and numerous factors are likely to be involved in dictating recurrence, progression and patient survival. While several molecular markers ...

This page focuses on rules for writing complete sentences that flow together to create a well written academic piece. This guide highlights common errors in structure and argument, and gives you a ...

Part of Biology (Single Science) Cells, organ systems and ecosystems ...

A new combination therapy of lurbinectedin and atezolizumab showed promising results in improving overall survival and progression-free survival in extensive-stage small cell lung cancer.